Accéder au contenu
Merck
  • Short interfering RNA-mediated silencing of actin-related protein 2/3 complex subunit 4 inhibits the migration of SW620 human colorectal cancer cells.

Short interfering RNA-mediated silencing of actin-related protein 2/3 complex subunit 4 inhibits the migration of SW620 human colorectal cancer cells.

Oncology letters (2018-02-13)
Xiaojuan Su, Siyang Wang, Yongxu Huo, Chunlei Yang
RÉSUMÉ

Actin-related protein 2/3 complex subunit 4 (ARPC4) acts as an actin nucleator in actin cytoskeleton branching and contributes to cell migration. ARPC4 has previously been demonstrated to be abnormally expressed in various colorectal carcinoma cell lines, particularly SW620 cells. The present study explored the biological action and the possible mechanisms underlying the function of ARPC4 in the progression of carcinoma. The proliferation and migration of SW620 cells transfected with ARPC4-specific short interfering (si)RNAs were assessed using western blot, cell counting, flow cytometry and transwell assays. SW620 cells exhibited the highest ARPC4 expression of the cell lines investigated, and siRNA538 was the most effective of the siRNAs considered. The results of the present study demonstrated that ARPC4-silencing exhibited a significant effect on the capacity of cells for migration, but did not affect their proliferative ability. ARPC4-silencing inhibited human SW620 cell migration, but not proliferation, in vitro, suggesting that ARPC4 may be a putative therapeutic target for colorectal carcinoma.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Conjugué anticorps anti-IgG de lapin (molécule entière)-peroxydase antibody produced in goat, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Conjugué anticorps anti-IgG de lapin (molécule entière)–phosphatase alcaline antibody produced in goat, IgG fraction of antiserum